Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$72 Mln
P/E Ratio
--
P/B Ratio
3.43
Industry P/E
--
Debt to Equity
2.97
ROE
-3.37 %
ROCE
-57.97 %
Div. Yield
0 %
Book Value
0.16
EPS
-0.33
CFO
$-156.83 Mln
EBITDA
$-186.88 Mln
Net Profit
$-271.01 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Biodesix Inc (BDSX)
| -64.77 | -35.10 | -47.67 | -57.22 | -30.85 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Biodesix Inc (BDSX)
| -16.72 | -20.00 | -56.52 | -73.76 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 139.56 | 11,164.80 | 13.01 | 159.08 | |
| 113.37 | 11,417.38 | 25.25 | 15.7 | |
| 122.10 | 11,522.86 | 3.73 | 110.75 | |
| 171.68 | 11,194.00 | 10.2 | 17.71 |
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in... identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado. Address: 919 West Dillon Road, Louisville, CO, United States, 80027 Read more
President, CEO & Director
Mr. Scott Hutton
President, CEO & Director
Mr. Scott Hutton
Headquarters
Louisville, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Biodesix Inc (BDSX) stood at $ 97 Mln as on 31-Dec-24
The share price of Biodesix Inc (BDSX) is $0.54 (NASDAQ) as of 25-Apr-2025 16:26 EDT. Biodesix Inc (BDSX) has given a return of -30.85% in the last 3 years.
Biodesix Inc (BDSX) has a market capitalisation of $ 72 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Biodesix Inc (BDSX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Biodesix Inc (BDSX) and enter the required number of quantities and click on buy to purchase the shares of Biodesix Inc (BDSX).
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado. Address: 919 West Dillon Road, Louisville, CO, United States, 80027
The CEO & director of Mr. Scott Hutton. is Biodesix Inc (BDSX), and CFO & Sr. VP is Mr. Scott Hutton.
There is no promoter pledging in Biodesix Inc (BDSX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,142
|
|
|
1,111
|
|
|
1,052
|
|
|
1,014
|
| Biodesix Inc (BDSX) | Ratios |
|---|---|
|
Return on equity(%)
|
-337.3
|
|
Operating margin(%)
|
-48.61
|
|
Net Margin(%)
|
-60.19
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Biodesix Inc (BDSX) was $0 Mln.
$-0.03
(
